The market for biosimilar versions of AbbVie’s mega-blockbuster TNF blocker Humira (adalimumab) is hotting up, with a major price reduction from Boehringer Inge 4 October 2023
Addressing what has been dubbed the ‘triple A’ challenge of access, affordability and availability has been an objective of the European Medicines Agency (EMA) 29 September 2023
The UK pharma industry has responded to proposed changes to the statutory scheme for branded medicines, arguing against their implementation. 29 September 2023
The inaugural report from the Access to Medicine Foundation's Generic and Biosimilar Medicines Program has taken a look at what five major industry players are 26 September 2023
Research is repeatedly showing that co-administration of individual drugs as combination therapy offers significant benefits to patients. 25 September 2023
The National Institute for Health and Care Excellence (NICE) has recommended Omvoh (mirikizumab) for the treatment of eligible adults in England and Wales with 22 September 2023
The National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) alongside lenalidomide and dexamethasone (DLd) for untreated 22 September 2023
Significant changes to the way European health technology assessments (HTA) take place is underway, with a transitional period set to be in force for several ye 18 September 2023
While legal challenges surrounding the implementation of the Inflation Reduction Act (IRA) continue to mount, the Centers for Medicare & Medicaid Services (CMS) 15 September 2023
The Belgian pharmaceutical industry has responded to reports of medicine shortages, with local media attributing the blame in some cases to the actions of pharm 11 September 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.